Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

scientific article

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1200/JCO.2015.63.9443
P8608Fatcat IDrelease_65vfrrk2wvd3noyedgwr5g2uia
P698PubMed publication ID26598747

P50authorDenis Moro-SibilotQ57054866
Alessandra BearzQ57079928
P2093author name stringDong-Wan Kim
Tarek Mekhail
Ramaswamy Govindan
Jin Seok Ahn
James Chih-Hsin Yang
Luigi De Petris
Sai-Hong Ignatius Ou
Peter N Morcos
Bogdana Balas
Hervé Lena
Ali Zeaiter
Walter Bordogna
Alexander Spira
Annabelle Monnet
Brett Hughes
Santiago Viteri Ramirez
P433issue7
P407language of work or nameEnglishQ1860
P921main subjectlung cancerQ47912
crizotinibQ5186964
P304page(s)661-668
P577publication date2015-11-23
P1433published inJournal of Clinical OncologyQ400292
P1476titleAlectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study
P478volume34

Reverse relations

cites work (P2860)
Q45069581"Neurological complications of new chemotherapy agents".
Q40996780A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases
Q33865475A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer
Q42357373A few pills twice a day keep ALK-positive non-small-cell lung cancer at bay.
Q33679543A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small-cell lung cancer
Q54978002A real-world study of treatment patterns and survival outcome in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Q33898894ALK Fusion Detection in Circulating Free DNA: Finding an Important Needle in the Haystack
Q46603813ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy
Q38820412ALK alterations and inhibition in lung cancer.
Q37209474ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations
Q52880860ALK inhibitors: plateauing systemic and intracranial activity?
Q52682025ALK-rearrangement in non-small-cell lung cancer (NSCLC).
Q55003764ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor.
Q42330754ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer
Q39718035ASCENDing the anaplastic lymphoma kinase ladder: a tale of two C-nibs
Q55022663Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects.
Q38763108Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC.
Q46143489Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
Q92286653Adverse Events of Concurrent Radiotherapy and ALK Inhibitors for Brain Metastases of ALK-Rearranged Lung Adenocarcinoma
Q64959585Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non-Small Cell Lung Cancer.
Q38846027Alectinib for ALK-positive non-small-cell lung cancer
Q53707445Alectinib for advanced ALK-positive non-small-cell lung cancer
Q41820718Alectinib for the management of ALK-positive non-small cell lung cancer brain metastases
Q38805618Alectinib for treatment of ALK-positive non-small-cell lung cancer
Q87970849Alectinib hydrochloride for non-small cell lung cancer
Q27853299Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Q64122275Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases
Q58802261Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy
Q47111470Alectinib in untreated anaplastic lymphoma kinase-positive non-small cell lung cancer
Q52580435Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
Q38787993Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Q93075388Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study
Q39669119Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series
Q37167686Alectinib, Ceritinib, Elotuzumab, and Venetoclax
Q92359322Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin
Q36906373Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
Q42434572Alectinib-a new chapter in the management of ALK-positive lung cancer
Q90377974Alectinib: A Review in Advanced, ALK-Positive NSCLC
Q38736644Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors
Q58616509Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces
Q42007490Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib
Q38872183Anaplastic lymphoma kinase inhibitors in elderly patients with advanced non-small cell lung cancer
Q92619272Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: a meta-analysis
Q39278116Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer
Q42356085Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as "ROS1" as it appears?
Q39665766Bioanalysis of alectinib and metabolite M4 in human plasma, cross-validation and impact on PK assessment
Q47110241Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer.
Q52318443Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment
Q39456912Brain Metastasis: Clinical Implications of Branched Evolution
Q58738654Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms
Q64238209Brigatinib for -positive metastatic non-small-cell lung cancer: design, development and place in therapy
Q89210654Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
Q91672755Bronchopleural fistula in squamous cell lung cancer following anlotinib treatment: A case report
Q33779505C3orf21 ablation promotes the proliferation of lung adenocarcinoma, and its mutation at the rs2131877 locus may serve as a susceptibility marker
Q57053257CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
Q43772415CNS Anticancer Drug Discovery and Development: 2016 conference insights
Q59135403Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer
Q30244613Ceritinib: A primer for pharmacists.
Q28073920China Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)
Q40372968China Experts Consensus on the Diagnosis and Treatment of Brain Metastases of Lung Cancer (2017 version)
Q90731627Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer
Q41605022Circulating tumor cells and CDX models as a tool for preclinical drug development
Q54178349Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib
Q64111067Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib
Q54977783Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review.
Q64119694Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer
Q42318174Control of brain metastases with alectinib in anaplastic lymphoma kinase-rearranged lung cancer
Q52682138Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer
Q26738381Crizotinib resistance: implications for therapeutic strategies
Q47114588Crizotinib-induced Rectal Perforation with Abscess
Q46080398Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
Q38735467Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
Q38816700Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.
Q42369337Current evidence in support of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor alectinib for the treatment of non-small cell lung cancer positive for ALK translocation
Q54980901Cystic brain metastases in ALK-rearranged non-small cell lung cancer.
Q55248131Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinomas of the Lung.
Q90411020Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins
Q47556226Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature review.
Q54631906Drug selection for anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Q42369295Editorial on the article entitled "brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial"
Q55017122Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects.
Q90566076Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
Q38938203Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies
Q51280223Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects
Q90356670Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases
Q57787347Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer
Q37688499Efficacy of D5F3 IHC for detecting ALK gene rearrangement in NSCLC patients: a systematic review and meta-analysis
Q50045235Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
Q90809080Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Q88497994Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies
Q55258220Emerging resistance pathways in lung cancer: what has ROS-1 taught us?
Q28070165Emerging therapeutic agents for lung cancer
Q38819472Emerging treatment for ALK-positive lung cancer
Q48013012Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead
Q46071509Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance
Q52644150Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.
Q90528991Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
Q38971627Experimental Treatments for Leptomeningeal Metastases From Solid Malignancies
Q50089402Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy
Q89996168Exploring the optimal use of alectinib
Q53684267Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
Q64109747Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance
Q54977963Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with ALK/ROS-1 mutations.
Q62808348Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer
Q28068643Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
Q90612116Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer
Q28079245Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients
Q42367836Genetic Characterization of Brain Metastases in the Era of Targeted Therapy.
Q38829087Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.
Q49662412Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
Q92236424Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study
Q37743107Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
Q53191682In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes.
Q38819317Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: A population-based study
Q54123036Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
Q38880324Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer
Q26768652Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer
Q37697125Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis
Q52722998J-ALEX trial will crown alectinib as the standard choice for anaplastic lymphoma kinase positive untreated non-small cell lung cancer patients?
Q51003952J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer
Q51147243LC-MS/MS determination of alectinib and its major human metabolite M4 in human urine: prevention of nonspecific binding
Q47707520Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib
Q33788680Leptomeningeal Carcinomatosis in Recurrent Non-Small Cell Lung Cancer: A Case Report and Review of Current Treatment Modalities
Q44772308Local thoracic therapy improve prognosis for stage IV non-small cell lung cancer patients combined with chemotherapy: A Surveillance, Epidemiology, and End Results database analysis
Q47599265Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
Q58607887Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Q50085932Lung cancer : What has been confirmed in therapy?
Q53117997Lung cancer as a cardiotoxic state: a review
Q61806101Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer
Q41130935Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report.
Q47333263Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development.
Q41636404Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Q26741320Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions
Q47141828Molecular Targets in Non-Small Cell Lung Cancer
Q47777234Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib
Q38696416Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
Q47108604Moving more potent and less toxic options to the frontline in the management of advanced lung cancer
Q64993243Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease.
Q98467276Multidisciplinary patient-centered management of brain metastases and future directions
Q41709220Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangement
Q48310841Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers.
Q33760992Nasogastric tube-administered alectinib achieved long-term survival in a crizotinib-refractory nonsmall cell lung cancer patient with a poor performance status
Q38947183New and emerging targeted treatments in advanced non-small-cell lung cancer.
Q92134597New generation anaplastic lymphoma kinase inhibitors
Q90809086Next-generation ALK inhibitors: is the median the message?
Q38650079Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study).
Q92988411Novel ProCore 25-gauge needle for endobronchial ultrasound-guided transbronchial needle aspiration reduces the puncture time and frequency, with comparable diagnostic rate for mediastinal and hilar lymphadenopathy
Q38809939Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer.
Q98612903Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors
Q39128273Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer
Q54116816Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience.
Q33591738Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
Q55710220Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer.
Q92988508Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era
Q49959323Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
Q58792324Personalized therapy for lung cancer: Striking a moving target
Q28071903Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
Q39095285Pharmacological management of relapsed/refractory NSCLC with chemical drugs
Q89360019Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9
Q38384492Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer
Q38688150Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.
Q33791836Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
Q52718657Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib
Q54467809Precision, accuracy, and resolution-Dose selection of oral anticancer agents
Q92236871Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
Q52661848Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib: A Case Report
Q55189638Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancer.
Q99711973Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
Q49307383Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA.
Q26747276Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC
Q54962187Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion.
Q47105316Recent advances in the management of non-small cell lung cancer
Q40626934Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma.
Q53565079Research Progress of Targeted Therapy for Anaplastic Lymphoma Kinase and Other Rare Driver Genes in Advanced Non-small Cell Lung Cancer
Q53718494Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
Q52720230Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer.
Q37388238Resisting Resistance: Targeted Therapies in Lung Cancer
Q33757138Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice
Q49888052Role and targeting of anaplastic lymphoma kinase in cancer
Q92635410Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review
Q41636361Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Q38748356Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer
Q47096145Saudi lung cancer management guidelines 2017.
Q42344252Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al.
Q39177404Sequencing brain metastases and opportunities for targeted therapies
Q38769610Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer
Q88345284Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
Q42673256Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
Q39139953Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives.
Q57168071Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date
Q55693260Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations.
Q58585573Symptom Management Strategies for Patients Receiving Anaplastic Lymphoma Kinase Inhibitors for Non-Small Cell Lung Cancer
Q54978820Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer.
Q64238220Systematic review of sequencing of ALK inhibitors in -positive non-small-cell lung cancer
Q54978262Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors.
Q30239901Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma
Q91845628TP53 mutations are predictive and prognostic when co-occurring with ALK rearrangements in lung cancer
Q26740329Tackling ALK in non-small cell lung cancer: the role of novel inhibitors
Q26738986Targeted therapies and immunotherapy in non-small-cell lung cancer
Q49961144Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma
Q47351169Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors
Q38815297Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
Q49956245Targeted therapy of brain metastases: latest evidence and clinical implications
Q38673845Targeting ALK-rearranged non-small-cell lung cancer: an update
Q39103431Targeting ALK: Precision Medicine Takes on Drug Resistance
Q38635259The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions
Q95841195The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients
Q89454905The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib
Q42357319The J-ALEX trial-is frontline alectinib a new standard of care?
Q91720704The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
Q33553447The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers
Q47115593The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor
Q39400469The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy.
Q38884328The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.
Q51740588The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis
Q55342455The emerging treatment landscape of advanced non-small cell lung cancer.
Q91709281The impact of systemic precision medicine and immunotherapy treatments on brain metastases
Q89497176The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era
Q38981789The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer
Q90243578The role of cytology in molecular testing and personalized medicine in lung cancer: A clinical perspective
Q64975085The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis.
Q38906188Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.
Q89493530Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies
Q54967334Treating ALK-positive non-small cell lung cancer.
Q39039088Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it.
Q90132769Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer
Q38730533Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design
Q38631019Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context
Q61810591Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line - Indian consensus statement update
Q52679023Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
Q37669352Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
Q38887451Updates in the management of brain metastases.
Q42340605What is the optimal first-line treatment for advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer?

Search more.